Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma.

Trial Profile

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin; Melphalan; Thalidomide; Vincristine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Millennium
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Apr 2016 Pooled pharmacogenomics genome-wide association study analysis (n=598) of 3 trials [IFM 2005-01, IFM2007-02, and HOVON-65/GMMG-HD4 ] were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 08 Dec 2015 Results of long term follow up presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top